Calcification process in bioprosthetic tissue

The calcification process in bioprosthetic tissue is a multifactorial and active degenerative pathway responsible for the leading mode of failure in bioprosthetic heart valves and soft tissue implants[1][2]. It results from a combination of host-immune responses (involving cytokines such as TNF-α, IL-1β, and IL-6), oxidative stress, lipid deposition (especially oxidized LDL), and extracellular matrix breakdown. Pathways include infiltration by inflammatory cells, osteogenic transformation of resident (valve interstitial) cells, and mineralization of cellular debris and ECM. Material-specific factors, such as residual aldehyde groups from glutaraldehyde cross-linking, can nucleate calcium deposition. Current and investigational interventions largely focus on modifying inflammatory responses, stabilizing ECM, or directly altering the chemical milieu to prevent calcium-phosphate crystal formation[1][2].

Other names

Bioprosthetic heart valve calcificationBioprosthetic tissue mineralizationBHV calcificationStructural valve degeneration via calcification

Mechanisms of action for interventions targeting this process include inhibition of inflammatory cytokine production (for anti-inflammatory agents), reduction of lipid oxidation and immune cell infiltration (for statins), inhibition of calcium-phosphate crystal nucleation (for bisphosphonates), and stabilization and modification of ECM to prevent calcium binding (for novel cross-linkers).